Loading the procedure…
Loading the procedure…
Medicare volume, surgeons, state markets and device makers
ACDF, posterior cervical fusion, cervical total disc replacement. Main billing specialties: neurosurgery and orthopedic spine.
Medicare fee-for-service cervical fusion & disc arthroplasty cases in the 49 states summed: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (210 state-years, 2020–2024): a close guide.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Texas | 91 | 4,236−3.4%/yr | −3.4%/yr | 1.91.3× | 3% | 4,580 in 2030+1.3%/yr |
| Florida | 85 | 3,684−1%/yr | −1%/yr | 1.61.1× | 7% | 4,300 in 2030+2.6%/yr |
| California | 77 | 3,603−4%/yr | −4%/yr | 1.00.7× | 0% | 4,270 in 2030+2.9%/yr |
| New York | 35 | 1,875−1.6%/yr | −1.6%/yr | 1.00.7× | 2% | 1,980 in 2030+0.9%/yr |
| Pennsylvania | 23 | 1,803−4.6%/yr | −4.6%/yr | 1.30.9× | 0% | 1,920 in 2030+1%/yr |
| Ohio | 25 | 1,738−4.6%/yr | −4.6%/yr | 1.51.1× | 5% | 1,920 in 2030+1.7%/yr |
| North Carolina | 26 | 1,686−6.3%/yr | −6.3%/yr | 1.61.2× | 6% | 1,550 in 2030−1.4%/yr |
| Georgia | 34 | 1,567−5.6%/yr | −5.6%/yr | 1.71.2× | 7% | 1,710 in 2030+1.4%/yr |
| Virginia | 35 | 1,533−3.6%/yr | −3.6%/yr | 1.41.0× | 1% | 1,680 in 2030+1.6%/yr |
| Illinois | 28 | 1,515−7.1%/yr | −7.1%/yr | 1.10.7× | 2% | 1,670 in 2030+1.6%/yr |
| Maryland | 34 | 1,470−1.4%/yr | −1.4%/yr | 1.61.2× | 5% | 1,510 in 2030+0.4%/yr |
| Tennessee | 32 | 1,388−3%/yr | −3%/yr | 1.91.3× | 6% | 1,430 in 2030+0.5%/yr |
| Michigan | 24 | 1,338−6.2%/yr | −6.2%/yr | 1.51.1× | 3% | 1,110 in 2030−3%/yr |
| Arizona | 36 | 1,337+2.4%/yr | +2.4%/yr | 1.71.2× | 6% | 1,730 in 2030+4.4%/yr |
| Missouri | 25 | 1,166−5.8%/yr | −5.8%/yr | 1.81.3× | 1% | 1,250 in 2030+1.1%/yr |
| Massachusetts | 23 | 1,163−2.2%/yr | −2.2%/yr | 1.20.8× | 0% | 1,360 in 2030+2.6%/yr |
| South Carolina | 31 | 1,151−3.6%/yr | −3.6%/yr | 1.61.1× | 4% | 1,220 in 2030+0.9%/yr |
| Colorado | 24 | 1,147−1.6%/yr | −1.6%/yr | 2.31.6× | 1% | 1,280 in 2030+1.9%/yr |
| Indiana | 21 | 997−4.8%/yr | −4.8%/yr | 1.41.0× | 3% | 960 in 2030−0.6%/yr |
| Louisiana | 21 | 996−3.3%/yr | −3.3%/yr | 2.31.7× | 2% | 1,040 in 2030+0.8%/yr |
| New Jersey | 15 | 957+0.5%/yr | +0.5%/yr | 0.90.6× | 0% | 1,050 in 2030+1.5%/yr |
| Alabama | 31 | 919−9.6%/yr | −9.6%/yr | 2.01.4× | 4% | 880 in 2030−0.7%/yr |
| Oklahoma | 28 | 913−6.1%/yr | −6.1%/yr | 1.81.3× | 0% | 980 in 2030+1.2%/yr |
| Washington | 12 | 886−6.9%/yr | −6.9%/yr | 1.10.8× | 11% | 890 in 20300%/yr |
| Minnesota | 9 | 723−4.6%/yr | −4.6%/yr | 1.51.1× | 0% | 840 in 2030+2.4%/yr |
| Kansas | 11 | 616−1.8%/yr | −1.8%/yr | 1.51.0× | 0% | 710 in 2030+2.5%/yr |
| Oregon | 11 | 615−5.6%/yr | −5.6%/yr | 1.41.0× | 25% | 690 in 2030+2%/yr |
| Kentucky | 10 | 605−9.7%/yr | −9.7%/yr | 1.30.9× | 2% | 730 in 2030+3.1%/yr |
| Arkansas | 15 | 594−6.2%/yr | −6.2%/yr | 1.51.1× | 5% | 650 in 2030+1.4%/yr |
| Mississippi | 13 | 506−7.3%/yr | −7.3%/yr | 1.30.9× | 24% | 500 in 2030−0.3%/yr |
| Wisconsin | 3 | 479−5.3%/yr | −5.3%/yr | 0.80.6× | 4% | 730 in 2030+7.3%/yr |
| Utah | 9 | 439−3.4%/yr | −3.4%/yr | 1.91.4× | 17% | 560 in 2030+4.1%/yr |
| Iowa | 9 | 408+2.6%/yr | +2.6%/yr | 0.90.6× | 3% | 500 in 2030+3.4%/yr |
| Nebraska | 8 | 406−2.1%/yr | −2.1%/yr | 1.51.1× | 6% | 480 in 2030+2.7%/yr |
| Connecticut | 4 | 398−6.3%/yr | −6.3%/yr | 1.20.8× | 0% | 400 in 2030+0.2%/yr |
| Nevada | 3 | 378−6.4%/yr | −6.4%/yr | 1.30.9× | 0% | 370 in 2030−0.3%/yr |
| Idaho | 8 | 341−3.9%/yr | −3.9%/yr | 1.61.1× | 0% | 450 in 2030+4.8%/yr |
| Delaware | 7 | 283−1.8%/yr | −1.8%/yr | 1.61.1× | 15% | 360 in 2030+4%/yr |
| Montana | 4 | 238−0.9%/yr | −0.9%/yr | 1.20.9× | 0% | 270 in 2030+2.1%/yr |
| Alaska | 5 | 221+8.1%/yr | +8.1%/yr | 1.81.3× | 0% | 400 in 2030+10%/yr |
| South Dakota | 4 | 201−1.4%/yr | −1.4%/yr | 1.51.1× | 0% | 270 in 2030+4.8%/yr |
| West Virginia | 2 | 183−11%/yr | −11%/yr | 0.80.6× | 0% | 160 in 2030−2.2%/yr |
| New Hampshire | 2 | 171−9.5%/yr | −9.5%/yr | 0.70.5× | 0% | 180 in 2030+0.7%/yr |
| District of Columbia | 2 | 158−2.2%/yr | −2.2%/yr | 2.51.7× | 10% | 160 in 2030−0.2%/yr |
| North Dakota | 3 | 152−5.1%/yr | −5.1%/yr | 1.51.0× | 0% | 160 in 2030+0.6%/yr |
| New Mexico | 2 | 123−6.5%/yr | −6.5%/yr | 0.50.4× | 0% | 250 in 2030+13%/yr |
| Rhode Island | 0 | 112−1%/yr | −1%/yr | 1.20.8× | 0% | 210 in 2030+11%/yr |
| Wyoming | 2 | 111−8.1%/yr | −8.1%/yr | 1.00.7× | 0% | 160 in 2030+6.2%/yr |
| Maine | 0 | 110−11%/yr | −11%/yr | 0.70.5× | 0% | 160 in 2030+6.5%/yr |
Professional codes (what the surgeon bills): CPT 22551, 22600, 22856; the hospital bills MS-DRG 471, 472, 473, 429, 430.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed, summed over the states listed: states MedaRep covers where the procedure tops 100 Medicare cases a year. All Medicare adds Medicare Advantage patients at each state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. How the numbers are made · Data sources
In the last 10 years FDA made 718 decisions (510(k) clearances, De Novo grants, PMA approvals and supplements) under this category’s product codes, held by 177 companies. The most active:
| Company | Decisions, 10 years |
|---|---|
| Highridge Medical | 53 |
| Globus Medical | 51 |
| Orthofix | 31 |
| Centinel Spine | 25 |
| Medtronic | 22 |
| Spinal Kinetics | 17 |
| VB Spine | 14 |
| Alphatec | 13 |
| Spineart | 11 |
| Vy Spine | 11 |
| Life Spine | 10 |
| Zavation Medical Products | 10 |
Product codes: KWP (appliance, fixation, spinal interlaminal), KWQ (appliance, fixation, spinal intervertebral body), MJO (prosthesis, intervertebral disc), NKG (posterior cervical screw system), ODP (intervertebral fusion device with bone graft, cervical), OVE (intervertebral fusion device with integrated fixation, cervical), PLR (spinal vertebral body replacement device - cervical). A company whose devices for this procedure are filed under other codes is not counted, and a PMA supplement counts as a decision of its own. Applicants are rolled up to their parent company.
The competitive landscape: each company scored on innovation pace, recall and report signals, commercial momentum and financial capacity.
Across the covered states the share outside the hospital has moved +2 pts since 2019, to 4%.
The 10 busiest do 23% of the cases CMS names in Texas; 63 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Procedure | Surgeons | Medicare FFS | Growth since 2019 | Forecast |
|---|---|---|---|---|
| Decompression & minimally invasive spine | 2,544 | 105,318−5.9%/yr | −5.9%/yr | 112,600 in 2030+1.1%/yr |
| Lumbar fusion | 2,352 | 95,082−1.5%/yr | −1.5%/yr | 107,700 in 2030+2.1%/yr |
| Kyphoplasty & vertebroplasty | 453 | 42,837−5.7%/yr | −5.7%/yr | 44,800 in 2030+0.7%/yr |
| SI joint fusion | 147 | 7,710+13%/yr | +13%/yr | 14,700 in 2030+11%/yr |
Every procedure · Markets by state · Device companies · Compare two states
In 2025, 37 companies reported engagement with surgeons in the covered states worth $8.8M in consulting, speaking, meals and travel tied to these products, about $9,175 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 69 clearances and approvals in the category, 4 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the state rankings. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.